参考文献/References:
[1] Hung ML,Lee EW.Role of Transjugular intrahepatic portosystemic shunt in the management of portal hypertension:review and update of the literature[J].Clin Liver Dis,2019,23:737-754.
[2]Boike JR,Thornburg BG,Asrani SK,et al.North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J].Clin Gastroenterol Hepatol,2022,20:1636-1662.e36.
[3]Casadaban LC,Parvinian A,Minocha J,et al.Clearing the confusion over hepatic encephalopathy after TIPS creation:Incidence,prognostic factors,and clinical outcomes[J].Dig Dis Sci,2015,60:1059-1066.
[4]Lv Y,Wang Q,Luo B,et al.Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding[J].J Hepatol,2025,82:245-257.
[5]Liu J,Ma J,Yang C,et al.Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement[J].Radiology,2022,303:711-719.
[6]Schindler P,Heinzow H,Trebicka J,et al.Shunt-induced hepatic encephalopathy in TIPS:current approaches and clinical challenges[J].J Clin Med,2020,9:3784.
[7]Xu L,He B,Sun Y,et al.Incidence of inflammatory bowel disease in Urban China:a nationwide population-based study[J].Clin Gastroenterol Hepatol,2023,21:3379.e 29-3386.e29.
[8]Lee EW,Kuei A,Saab S,et al.Nationwide trends and predictors of inpatient mortality in 83 884 transjugular intrahepatic portosystemic shunt[J].World J Gastroenterol,2016,22:5780-5789.
[9]Demirtas CO,D'Alessio A,Rimassa L,et al.ALBI grade:evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma[J].JHEP Rep,2021,3:100347.
[10]Peng Y,Wei Q,Liu Y,et al.Prediction and risk factors for prognosis of cirrhotic patients with hepatic encephalopathy[J].Gastroenterol Res Pract,2021,2021:5623601.
[11]Luo S,Zhou ZM,Guo DJ,et al.Radiomics-based classification models for HBV-related cirrhotic patients with covert hepatic encephalopathy[J].Brain Behav,2021,11:e01970.
[12]Zhong BY,Wang WS,Shen J,et al.Single-centre retrospective training cohort using artificial intelligence for prognostic prediction of encephalopathy,mortality,and liver dysfunction after early tips creation[J].Cardiovasc Intervent Radiol,2021,44:1597-1608.
[13]Zhang Z,Wang J,Han W,et al.Using machine learning methods to predict 28-day mortality in patients with hepatic encephalopathy[J].BMC Gastroenterol,2023,23:111.
[14]Li X,Partovi S,Coronado WM,et al.Hepatic encephalopathy after TIPS placement:Predictive factors,prevention strategies,and management[J].Cardiovasc Intervent Radiol,2022,45:570-577.
[15]Guarino A,Ashkenazi S,Gendrel D,et al.European Society for Pediatric Gastroenterology,Hepatology,and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe:update 2014[J].J Pediatr Gastroenterol Nutr,2014,59:132-152.
[16]Gairing SJ,Schleicher EM,Galle PR,et al.Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis[J].Hepatol Commun,2023,7:e0096.
[17]Gairing SJ,Müller L,Kloeckner R,et al.Review article:post-TIPSS hepatic encephalopathy-current knowledge and future perspectives[J].Aliment Pharmacol Ther,2022,55:1265-1276.
[18]Coronado WM,Ju C,Bullen J,et al.Predictors of occurrence and risk of hepatic encephalopathy after TIPS creation:a 15-year experience[J].Cardiovasc Intervent Radiol,2020,43:1156-1164.
[19]Li J,Feng D,Pang N,et al.Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt[J].Clin Nutr,2022,41:560-566.
[20]Li W,Duan Y,Liu Z,et al.Clinical value of hemodynamic changes in diagnosis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J].Scand J Gastroenterol,2022,57:713-718.
[21]Xia Y,Tie J,Wang G,et al.Individualized portal pressure gradient threshold based on liver function categories in preventing rebleeding after TIPS[J].Hepatol Int,2023,17:967-978.
[22]Luo SH,Zhou MM,Cai MJ,et al.Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications[J].World J Gastroenterol,2023,29:2336-2348.
[23]Bai Y,Liu J,Wu W,et al.Transjugular intrahepatic portosystemic shunt(TIPS)with variceal embolization reduces rebleeding risk for patients with portal pressure gradient over 12 mmHg:a long-term follow-up study[J].Eur J Radiol,2024,181:111740.
[24]陈 杨,刘家成,杨崇图,等.经颈静脉肝内门体分流术后肝性脑病预后因素研究进展[J].介入放射学杂志,2022,31:301-306.
[25]高西杰,赵剑波,谭 卿,等.Viatorr支架经颈静脉肝内门体分流术后显性肝性脑病发生率及其危险因素分析[J].介入放射学杂志,2021,30:998-1002.
[26]Cheng S,Yu X,Chen X,et al.CT-based radiomics model for preoperative prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J].Br J Radiol,2022,95:20210792.
[27]Berenguer M.Nutritional status in hepatic encephalopathy and transjugular intrahepatic portosystemic shunt:TIPS,and strategies to improve the outcomes[J].Acta Gastroenterol Belg,2023,86:318-322.
[28]Gairing SJ,Schleicher EM,Labenz C.Diabetes mellitus-risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis?[J].Metab Brain Dis,2023,38:1691-1700.
[29]Helzberg JH,Dai R,Muir AJ,et al.Socioeconomic status is associated with the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J].J Vasc Interv Radiol,2021,32:950-960.e1.
[30]Ridola L,Riggio O.Ammonia and prognosis of cirrhosis:a new perspective for identifying high-risk patients[J].J Hepatol,2023,78:e69-e70.
[31]Ballester MP,Tranah TH,Balcar L,et al.Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis[J].J Hepatol,2023,79:967-976.
[32]Yokoyama K,Fukuda H,Yamauchi R,et al.Long-term effects of rifaximin on patients with hepatic encephalopathy:its possible effects on the improvement in the blood ammonia concentration levels,hepatic spare ability and refractory ascites[J].Medicina(Kaunas),2022,58:1276.
[33]Murakami T,Shimizu H,Yogi N,et al.A Case of perihilar cholangiocarcinoma with postoperative hepatic encephalopathy due to portosystemic shunt treated by percutaneous embolization[J].Gan To Kagaku Ryoho,2023,50:102-104.
[34]张 亮,李 浩,汤善宏.肝硬化血氨相关肝性脑病的诊治思考[J].临床肝胆病杂志,2023,39:2942-2945.
[35]Xu XY,Ding HG,Li WG,et al.Chinese guidelines on management of hepatic encephalopathy in cirrhosis[J].World J Gastroenterol,2019,25:5403-5422.
[36]Li J,Liu Y,Li M,et al.Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS[J].Hepatol Commun,2023,7:e0128.
[37]Gairing SJ,Anders J,Kaps L,et al.Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis[J].Hepatol Commun,2022,6:1113-1122.
[38]Labenz C,Toenges G,Huber Y,et al.Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy[J].Aliment Pharmacol Ther,2019,50:1112-1119.
[39]Tan L,Meng Y,Zeng T,et al.Clinical diagnostic significance of prealbumin,cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy[J].Br J Biomed Sci,2019,76:24-28.
[40]Stockhoff L,Muellner-Bucsics T,Markova A,et al.Low serum cholinesterase identifies patients with worse outcome and increased mortality after TIPS[J].Hepatol Commun,2022,6:621-632.
[41]Decker SO,Krüger A,Wilk H,et al.Concurrent change in serum cholinesterase activity and midregional-proadrennomedullin level could predict patient outcome following liver transplantation[J].Biomolecules,2022,12:989.
[42]Liu D,Li J,Lu W,et al.Gamma-glutamyl transpeptidase to cholinesterase and platelet ratio in predicting significant liver fibrosis and cirrhosis of chronic hepatitis B[J].Clin Microbiol Infect,2019,25:514.e1-514.e8.
[43]Aghdassi A,Schwedhelm E,Atzler D,et al.The relationship between homoarginine and liver biomarkers:a combination of epidemiological and clinical studies[J].Sci Rep,2023,13:5230.
[44]Yang C,Zhu X,Liu J,et al.Development and validation of prognostic models to estimate the risk of overt hepatic encephalopathy after TIPS creation:a multicenter study[J].Clin Transl Gastroenterol,2022,13:e00461.
[45]Yang Y,Liang X,Yang S,et al.Preoperative prediction of overt hepatic encephalopathy caused by transjugular intrahepatic portosystemic shunt[J].Eur J Radiol,2022,154:110384.
[46]Liu J,Zhou C,Wang Y,et al.The combination of Child-Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J].Abdom Radiol(NY),2021,46:3464-3470.
[47]Bettinger D,Thimme R,Schultheiss M.Reply to:Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival"[J].J Hepatol,2021,75:749-750.
[48]Wang Z,Wu YF,Yue ZD,et al.Comparative study of indocyanine green-R15,Child-Pugh score,and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J].World J Gastroenterol,2021,27:416-427.
[49]Pasricha TS,Kochar B.Vaping-associated esophagitis[J].BMC Gastroenterol,2021,21:106.
[50]Yang S,Zhang L,Jin Q,et al.Meld-sarcopenia score and skeletal muscle density predicts short-term readmission of patients with hepatic encephalopathy[J].Eur J Radiol,2023,169:111178.
[51]Alessandria C,Gaia S,Marzano A,et al.Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment[J].Eur J Gastroenterol Hepatol,2004,16:607-612.
[52]Allegretti AS,Ortiz G,Cui J,et al.Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis:a matched cohort analysis[J].Am J Kidney Dis,2016,68:381-391.
[53]Anderson CL,Saad WE,Kalagher SD,et al.Effect of transjugular intrahepatic portosystemic shunt placement on renal function:a 7-year,single-center experience[J].J Vasc Interv Radiol,2010,21:1370-1376.
[54]Ding W,Shen J,Zhang L,et al.A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure[J].Front Med(Lausanne),2024,11:1406275.
[55]Toyoda H,Johnson PJ.The ALBI score:From liver function in patients with HCC to a general measure of liver function[J].JHEP Rep,2022,4:100557.
[56]Hiraoka A,Kumada T,Michitaka K,et al.Newly proposed ALBI grade and ALBI-T Score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients[J].Liver Cancer,2019,8:312-325.
[57]Navadurong H,Thanapirom K,Wejnaruemarn S,et al.Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis[J].World J Gastroenterol,2023,29:4873-4882.
[58]de Franchis R,Bosch J,Garcia-Tsao G,et al.Baveno Ⅶ:renewing consensus in portal hypertension[J].J Hepatol,2022,76:959-974.
[59]Cai W,Zheng B,Lin X,et al.Prediction of patient hepatic encephalopathy risk with freiburg index of post-TIPS survival score following transjugular intrahepatic portosystemic shunts:a retrospective study[J].Int J Gen Med,2022,15:4007-4016.
[60]Sturm L,Schultheiss M,Stohr F,et al.The freiburg index of post-TIPS survival(FIPS)identifies patients at risk for further decompensation and ACLF after TIPS[J].J Hepatol,2025:S0168-8278(25)00067-00064.
[61]Huang Z,Yao Q,Zhu J,et al.Efficacy and safety of transjugular intrahepatic portosystemic shunt(TIPS)created using covered stents of different diameters:a systematic review and meta-analysis[J].Diagn Interv Imaging,2021,102:279-285.
[62]Parlati L,Régnier M,Guillou H,et al.New targets for NAFLD[J].JHEP Rep,2021,3:100346.
[63]Bosch J.Small diameter shunts should lead to safe expansion of the use of TIPS[J].J Hepatol,2021,74:230-234.
[64]Lv Y,Wang Q,Luo B,et al.Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding[J].J Hepatol,2025,82:245-257.
[65]Lacy BE,Chan JL.Physician burnout:The hidden health care crisis[J].Clin Gastroenterol Hepatol,2018,16:311-317.
[66]Liu J,Ma J,Zhou C,et al.Potential benefits of underdilation of 8-mm covered stent in transjugular intrahepatic portosystemic shunt creation[J].Clin Transl Gastroenterol,2021,12:e00376.
[67]郑 晖,杨维竹,黄 宁,等.不同直径覆膜支架行经颈静脉肝内门体分流术治疗食管胃底静脉曲张破裂出血[J].介入放射学杂志,2018,27:167-171.
[68]Khattak A,Mehak Z,Ahmad H,et al.Customer churn prediction using composite deep learning technique[J].Sci Rep,2023,13:17294.
[69]Khalifa A,Obeid JS,Erno J,et al.The role of artificial intelligence in hepatology research and practice[J].Curr Opin Gastroenterol,2023,39:175-180.
[70]Dantas Machado AC,Ramos SF,Gauglitz JM,et al.Portosystemic shunt placement reveals blood signatures for the development of hepatic encephalopathy through mass spectrometry[J].Nat Commun,2023,14:5303.
[71]Durso AM,Paes FM,Caban K,et al.Evaluation of penetrating abdominal and pelvic trauma[J].Eur J Radiol,2020,130:109187.
[72]Ronald J,Bozdogan E,Zaki IH,et al.Relative sarcopenia with excess adiposity predicts survival after transjugular intrahepatic portosystemic shunt creation[J].AJR Am J Roentgenol,2020,214:200-205.
[73]Cai W,Lin H,Qi R,et al.Psoas muscle density predicts occurrences of hepatic encephalopathy in patients receiving transjugular intrahepatic portosystemic shunts within 1 year[J].Cardiovasc Intervent Radiol,2022,45:93-101.
[74]Ince O,Onder H,Genctürk M,et al.Machine learning insights:predicting hepatic encephalopathy after TIPS placement[J].Cardiovasc Intervent Radiol,2023,46:1715-1725.
[75]黄良江,毛德文,郑景辉,等.人工智能在肝性脑病风险预测模型中的应用进展[J].实用医学杂志,2024,40:289-294.
[76]Das D,Ito J,Kadowaki T,et al.An interpretable machine learning model for diagnosis of Alzheimer's disease[J].PeerJ,2019,7:e6543.
(收稿日期:2024-12-12)
(本文编辑:谷 珂)